Record-Breaking Price Performance
On 7 July 2026, Parmax Pharma Ltd’s share price touched Rs.86.22, setting a new 52-week and all-time high. The stock opened with a 2.00% gain and maintained this level throughout the trading session, outperforming its sector by 1.74%. This price surge is part of a broader upward trajectory, with the stock registering gains for 21 consecutive trading days, delivering an impressive 88.54% return during this period.
Comparatively, the benchmark Sensex recorded a modest 0.31% gain on the same day, underscoring Parmax Pharma’s relative strength in the market. The stock’s performance over various time frames further highlights its robust momentum: a 10.38% rise over the past week, an 88.54% increase over the last month, and a staggering 178.94% gain over three months. Year-to-date, the stock has surged 154.86%, while the Sensex has declined by 7.85%.
Technical Indicators Confirm Bullish Momentum
Technical analysis reveals a predominantly bullish trend for Parmax Pharma Ltd. The current trend, which shifted to bullish on 8 June 2026 at a price of Rs.48.81, is supported by multiple indicators. Weekly and monthly MACD, Bollinger Bands, KST, and Dow Theory indicators all signal bullish momentum. Although the Relative Strength Index (RSI) shows bearish tendencies on both weekly and monthly scales, the overall technical outlook remains positive.
The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the strength of the upward trend. Immediate support is identified at Rs.22.60, the 52-week low, while the recent all-time high at Rs.86.22 now serves as a major resistance level.
Delivery Volumes and Market Activity
Market activity has intensified alongside the price rally. Delivery volumes have surged significantly, with a 185.2% increase in one-day delivery volume compared to the five-day average. Over the trailing month from 6 June to 6 July 2026, average delivery volumes stood at 6.76 thousand shares, up from 5.32 thousand in the previous month. This heightened trading activity reflects growing market participation in the stock’s upward movement.
Valuation Metrics and Financial Overview
Despite the strong price performance, Parmax Pharma Ltd remains a loss-making entity, with no reported price-to-earnings (P/E) ratio due to negative earnings. The price-to-book value ratio stands at -5.14x, and the enterprise value to EBITDA ratio is -11.87x, indicating valuation challenges typical of companies in early growth or turnaround phases.
The company’s EV/Sales ratio is 3.51x, and EV/Capital Employed is 9.00x. Dividend metrics are not applicable as the company has not declared dividends recently. The stock’s 52-week range spans from a low of Rs.22.60 to the current high of Rs.86.22, representing a 281.50% increase from the low point.
Quality and Financial Trends
Parmax Pharma Ltd’s overall quality grade is assessed as below average, reflecting challenges in long-term financial performance. Key quality factors include a 5-year sales decline of 14.30% and a significant 225.63% decrease in EBIT over the same period. The company maintains a net cash position with negative net debt and no promoter share pledging, which are positive indicators for financial stability.
Return on capital employed (ROCE) and return on equity (ROE) remain weak at -28.89% and 5.12% respectively. The tax ratio is 100%, and the company has not paid dividends, consistent with its loss-making status. Short-term financial trends as of March 2026 indicate some negative aspects, including a 50.12% decline in profit after tax (PAT) over nine months and a 31.23% reduction in net sales over the latest six months.
Market Position and Sector Context
Operating within the Pharmaceuticals & Biotechnology sector, Parmax Pharma Ltd’s stock performance has notably outpaced the broader market and sector indices. Over three years, the stock has appreciated by 195.27%, compared to a 20.29% gain in the Sensex. Over five years, the stock’s 71.24% return also exceeds the Sensex’s 48.01% gain, although the 10-year performance remains flat at 0.00%.
This recent surge to an all-time high underscores a significant phase of market recognition and price appreciation for the company, despite underlying financial and quality challenges.
Mojo Score and Market Sentiment
According to MarketsMOJO, Parmax Pharma Ltd holds a Mojo Score of 31.0 with a current Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 8 June 2026. The stock is classified as a micro-cap, reflecting its relatively small market capitalisation and associated liquidity considerations.
The upgrade in rating coincides with the stock’s recent bullish trend and price appreciation, indicating a shift in market sentiment despite ongoing financial headwinds.
Summary
Parmax Pharma Ltd’s stock reaching an all-time high of Rs.86.22 on 7 July 2026 marks a noteworthy milestone in its market journey. The stock’s sustained gains over the past three months and year-to-date performance have significantly outperformed the Sensex and sector benchmarks. Supported by a strong technical trend and increased market activity, the stock’s price appreciation reflects a period of robust market momentum.
While valuation and quality metrics highlight areas of caution, the company’s net cash position and absence of promoter pledging provide some financial stability. The recent upgrade in Mojo Grade from Strong Sell to Sell further illustrates evolving market perspectives. Overall, Parmax Pharma Ltd’s achievement of a new all-time high is a significant event within the Pharmaceuticals & Biotechnology sector, underscoring the dynamic nature of its stock performance.
